Deciphering the suppressive immune microenvironment of prostate cancer based on CD4+ regulatory T cells: Implications for prognosis and therapy prediction

Qintao Ge; Zhijie Zhao; Xiao Li; Feixiang Yang; Meng Zhang; Zongyao Hao; Chaozhao Liang; Jialin Meng

doi:10.1002/ctm2.1552

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (1) : e1552 DOI: 10.1002/ctm2.1552

LETTER TO THE JOURNAL

Deciphering the suppressive immune microenvironment of prostate cancer based on CD4+ regulatory T cells: Implications for prognosis and therapy prediction

Qintao Ge ¹^,²^,³
, Zhijie Zhao ⁴
, Xiao Li ¹^,²^,³
, Feixiang Yang ¹^,²^,³
, Meng Zhang ¹^,²^,³
, Zongyao Hao ¹^,²^,³
, Chaozhao Liang ¹^,²^,³^,⁵
, Jialin Meng ¹^,²^,³^,⁵^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Qintao Ge, Zhijie Zhao, Xiao Li, Feixiang Yang, Meng Zhang, Zongyao Hao, Chaozhao Liang, Jialin Meng. Deciphering the suppressive immune microenvironment of prostate cancer based on CD4+ regulatory T cells: Implications for prognosis and therapy prediction. Clinical and Translational Medicine, 2024, 14(1): e1552 DOI:10.1002/ctm2.1552

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Beer TM, Kwon ED, Drake CG, et al. Randomized, double-blind, phase iii trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35(1):40-47.

[2]	Meng J, Zhou Y, Lu X, et al. Immune response drives outcomes in prostate cancer: implications for immunotherapy. Mol Oncol. 2021;15(5):1358-1375.

[3]	Downs-Canner S, Berkey S, Delgoffe GM, et al. Suppressive IL-17A(+)Foxp3(+) and ex-Th17 IL-17A(neg)Foxp3(+) T(reg) cells are a source of tumour-associated T(reg) cells. Nat Commun. 2017;8:14649.

[4]	Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity. 2019;50(4):924-940.

[5]	Jiao S, Subudhi SK, Aparicio A, et al. Differences in tumor microenvironment Dictate T helper lineage polarization and response to immune checkpoint therapy. Cell. 2019;179(5):1177-1190. e13

[6]	Maxwell KN, Cheng HH, Powers J, et al. Inherited TP53 variants and risk of prostate cancer. Eur Urol. 2021;81:243-250.

[7]	Chen X, Zhang T, Su W, et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2022;13(11):974.

[8]	Jiang Z, Liu Z, Li M, Chen C, Wang X. Immunogenomics analysis reveals that TP53 mutations inhibit tumor immunity in gastric cancer. Transl Oncol. 2018;11(5):1171-1187.

[9]	Pungsrinont T, Kallenbach J, Baniahmad A. Role of PI3K-AKT-mTOR pathway as a pro-survival signaling and resistance-mediating mechanism to therapy of prostate cancer. Int J Mol Sci. 2021;22(20).

[10]	Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575-586.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.